Affiliation:
1. Department of Molecular Microbiology and Immunology, School of Hygiene and Public Health, Johns Hopkins University, Baltimore, Maryland 21205,1 and
2. Department of Molecular and Cell Biology, University of California, Berkeley, California 947202
Abstract
ABSTRACT
Pyrazinamide (PZA) is an important antituberculosis drug. Unlike most antibacterial agents, PZA, despite its remarkable in vivo activity, has no activity against
Mycobacterium tuberculosis
in vitro except at an acidic pH.
M. tuberculosis
is uniquely susceptible to PZA, but other mycobacteria as well as nonmycobacteria are intrinsically resistant. The role of acidic pH in PZA action and the basis for the unique PZA susceptibility of
M. tuberculosis
are unknown. We found that in
M. tuberculosis
, acidic pH enhanced the intracellular accumulation of pyrazinoic acid (POA), the active derivative of PZA, after conversion of PZA by pyrazinamidase. In contrast, at neutral or alkaline pH, POA was mainly found outside
M. tuberculosis
cells. PZA-resistant
M. tuberculosis
complex organisms did not convert PZA into POA. Unlike
M. tuberculosis
, intrinsically PZA-resistant
M. smegmatis
converted PZA into POA, but it did not accumulate POA even at an acidic pH, due to a very active POA efflux mechanism. We propose that a deficient POA efflux mechanism underlies the unique susceptibility of
M. tuberculosis
to PZA and that the natural PZA resistance of
M. smegmatis
is due to a highly active efflux pump. These findings may have implications with regard to the design of new antimycobacterial drugs.
Publisher
American Society for Microbiology
Subject
Molecular Biology,Microbiology